Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Rating) to report $9.15 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for CASI Pharmaceuticals’ earnings. The lowest sales estimate is $8.60 million and the highest is $9.70 million. CASI Pharmaceuticals posted sales of $5.74 million during the same quarter last year, which would suggest a positive year over year growth rate of 59.4%. The business is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that CASI Pharmaceuticals will report full year sales of $42.45 million for the current year, with estimates ranging from $40.10 million to $44.80 million. For the next financial year, analysts anticipate that the firm will report sales of $112.18 million, with estimates ranging from $105.06 million to $119.30 million. Zacks’ sales calculations are an average based on a survey of research firms that cover CASI Pharmaceuticals.
CASI Pharmaceuticals (NASDAQ:CASI – Get Rating) last issued its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. CASI Pharmaceuticals had a negative return on equity of 40.06% and a negative net margin of 121.50%. During the same period in the previous year, the business earned ($0.12) earnings per share.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CASI. Marshall Wace LLP increased its stake in CASI Pharmaceuticals by 325.6% in the 3rd quarter. Marshall Wace LLP now owns 952,037 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 728,328 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of CASI Pharmaceuticals by 128.8% during the 4th quarter. Susquehanna International Group LLP now owns 531,064 shares of the biotechnology company’s stock valued at $425,000 after purchasing an additional 298,955 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of CASI Pharmaceuticals by 34.2% during the 3rd quarter. Geode Capital Management LLC now owns 944,729 shares of the biotechnology company’s stock valued at $1,124,000 after purchasing an additional 240,841 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of CASI Pharmaceuticals by 930.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 218,428 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 197,236 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of CASI Pharmaceuticals by 143.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 151,183 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 89,131 shares during the last quarter. 46.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CASI stock traded down $0.03 during trading hours on Friday, reaching $0.62. The company had a trading volume of 191,191 shares, compared to its average volume of 402,695. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.88. CASI Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $1.99.
CASI Pharmaceuticals Company Profile (Get Rating)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
- Get a free copy of the StockNews.com research report on CASI Pharmaceuticals (CASI)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.